Roche bolstered the Swiss pharma giant’s diagnostics capabilities by acquiring the company’s long-term partner, TIB Molbiol. The procurement will expand Roche’s PCR-test portfolio capabilities in the ongoing fight against existing and emerging infectious diseases, including new Covid-19 variants of interest.
BioSpace takes a look at the flurry of expansion activity in the life sciences industry as biopharma and diagnostic companies expand manufacturing sites.
Swiss drugmaker Roche predicted on April 21 that demand for the company’s drugs would accelerate for the remainder of 2021, after first-quarter sales of Covid-19 tests offset a pandemic-influenced slump in its main pharmaceuticals business.
For the second year in a row, California-based Agilent Technologies – a leader in diagnostics and applied chemical markets – was ranked as one of Barron’s most sustainable companies.
While the world has largely been focused on the development of vaccines and therapeutics for Covid-19, the U.S. Food and Drug Administration has remained busy lining up potential approvals of medications for other diseases and illnesses.
The Consistent Testing Terminology Working Group published a white paper with industry-wide recommendations for precision medicine testing terms to be utilized in patient education and communication.
Roche struck a $1.7 billion cancer drug pact with Blueprint Medicines, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.
Quest Diagnostics saw a higher recovery in the company’s testing volumes in the United States where state and local governments were slowly lifting restrictions after the coronavirus lockdowns.
The U.S. Food and Drug Administration approved drugmaker Eli Lilly and Co.’s radioactive compound to detect tau, an important characteristic of Alzheimer’s disease.
Recent updates include the U.S. FDA posting a list of antibody tests that are being withdrawn voluntarily by the test’s commercial manufacturer.